A bit more about PR dearth & reasons why. (Date 1/2/2004) email reply from David Steen of Xenotech:
Hello, I apologize for the delay in responding to your email; I contacted the flu and have been sick since shortly after we talked. My comments are as follows:
Might want to explain that the testing we are doing, is to demonstrate the degree to which the MultiCell hepatocytes duplicate the functions of normal human hepatocytes, and maybe give a range that the testing will take between four to ten weeks from now (which puts mid-February in the middle, but also allows for a little more time if needed. The reason that we might need a little more time is if we find something that looks good, but needs a little trial-and-error, or refinement of experimental conditions, to gain optimum results from the MCT cells.)
Whatever data we develop, will be communicated to the industry via scientific, continuing-education conferences, on-site presentations, and posters and papers. Or, another way to say it, is that XenoTech won't "pre-release" such findings because, if word gets out that we have, our submissions of papers, posters, and requests to present at conferences, will likely be rejected. Thus, you may want to alert people to not expect some press-release type of announcement from XenoTech about any results from concluded experiments, nor to try to inquire from us about any findings, because normal industry protocols prevent us from doing so.
Last comment regarding your suit analogy; I'm thinking you might want to simply mention that's your way of depicting my description of the process. Not that there's anything wrong with the analogy, just to explain that that, and the related comment about patience in holding the stock are your thoughts. I wouldn't want to be interpreted as making a stock recommendation one way or the other.
Sincerely,
David Steen Vice-President of Business Development XenoTech LLC
News 
Market Data 
Discover 
AI
